1 5%
J j

PTO/SB/30 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031 rademark Office: U.S. DEPARTMENT OF COMMERCE

	U.S. Faterit and Traderi	nark Onice, C.C. DEI rattimetti G.
	no persons are required to respond to a collection of informat	tion unless it contains a valid OMR control number
with the Department Poduction Act of 1995	no nersons are required to respond to a collection of informat	ion unless it contains a valid Civib control name
nder the Paperwork Reduction Act of 1990	the percent are require	

Request For Continued Examination (RCE) **Transmittal**

Address to: Commissioner for Patents **Box RCE** Alexandria, VA 22313

ed to respond to a collection of informa	Illion unless it contains a valid only control notice	41
Application Number	09/966,202	min.
Filing Date	September 26, 2001	8/26/03
First Named Inventor	Belloni, Paula	EIVA
Art Unit	1616	2 2003
Examiner Name	George, Konata M.	2003
Attorney Docket Number	R0086B-DIV	1600/29 00
nder 37 CFR 1.114 of the ab	inty of plant application flica prior to durie of	1 SOUTE 900

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1.	Submission required under 37 CFR 1.114				
	a. Previously submitted				
i	i. Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on May 15, 2003 (Any unentered amendment(s) referred to above will be entered).				
	li. Consider the arguments in the Appeal Brief or Rely Brief previously filed on				
	lii. Other a copy of the response faxed 5/15/2003 is enclosed				
	b. Enclosed				
	I. Amendment/Reply iii. Information Disclosure Statement (IDS)				
İ	ii. Affidavit(s)/ Declaration(s) iv. Other				
2.	Miscellaneous				
	Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)				
	b. Other				
3.	Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.				
	The Director is hereby authorized to charge the following fees, or credit any overpayments, to				
	Ser attached the service of the serv				
1	i. RCE fee required under 37 CFR 1.17(e) \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\				
	ii. Extension of time fee (37 CFR 1.136 and 1.17)				
	iii. Other 410.00 DA				
	b. Check in the amount of \$enclosed				
	c. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
Non	SIGNATURE OF PPLICANT, ATTORNEY, OR AGENT REQUIRED Registration No. (Attorney/Agent) 46,585				
Nan	ne (Print/Type) Brian L. Buckwalter Registration No. (Attorney/Agent) 46,585				

	SIGNAJĪURE OF PPLICA	NT, ATTORNEY, OR AGENT RE	QUIRED
Name (Print/Type)	Brian L. Buckwalter		tion No. (Attorney/Agent) 46,585
Signature	Mult Routiste	Date	August 18, 2003
	CERTIFICATE O	MAILING OR TRANSMISSION	
I hereby certify that thi addressed to: Commis shown below.	is correspondence is being deposited with the Unite ssioner For Patents, Box RCE, Washington, DC 20	ed States Postal Service with sufficient 231, or facsimile transmitted to the U.S	postage as first class mail in an envelope . Patent and Trademark Office on the date
Name (Print/Type)	Chris Myers		
Signature	prio Millo	Date	August 18, 2003
		Page I of 2	-

This collection of information is required by 37 CFR 114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, Box RCE, Washington, DG 20234.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CHARACTERS PATENT PATEN

	First Named Inventor	Paula Belloni
Address to:	Application Number	09/966,202
	Filing Date	September 26, 2001
Box AF	Group Art Unit	1616
Commissioner for Patents	Examiner	George, Konata M.
PO Box 1450	Attorney Docket No.	R0086B-DIV
Alexandria, VA 22313	Title	METHODS FOR THE TREATMENT OF EMPHYSEMA USING 13-CIS- RETINOIC ACID

AMENDMENT & RESPONSE UNDER 37 CFR §1.116

SIR:

In response to the Final Office Action dated March 17, 2003, having a shortened statutory period of response set to expire June 17, 2003, please amend the application as follows and take the following remarks into consideration:

Amendments to the specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 7 of this paper.